NewsHKSubscribe
Markets市場

SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® from Hansa Biopharma in €115 Million Deal

SERB Pharmaceuticals has agreed to acquire exclusive development and commercialization rights to Idefirix® (Imlifidase) from Swedish biotech Hansa Biopharma AB (Nasdaq Stockholm: HNSA) for €115 million, the companies announced in…

By Mara Whitfield·June 23, 2026·二〇二六年六月二十三日·2 min read

Source · 來源

globenewswire.com

Share · 分享
Xinfw
← Back to the News DeskFiled · Markets

Related Dispatches

相關報導
News Desk →
  1. 01Markets市場

    Datadog beats second-quarter earnings but fiscal 2026 profit guidance misses

    Enterprise software spending has been under pressure through the current rate cycle, as higher borrowing costs pushed corporate…

    August 6, 2026 · 2 min

  2. 02Markets市場

    Datadog shares fall as second-quarter beat and raised fiscal 2026 guidance fail to lift market sentiment

    Cloud software valuations have spent much of this cycle running ahead of the underlying spend commitments that move through…

    August 6, 2026 · 2 min

  3. 03Markets市場

    Eli Lilly earnings set to test obesity drug momentum

    The obesity drug market has drawn sustained investor attention across the pharmaceutical sector, and Eli Lilly and Company…

    August 4, 2026 · 2 min

Elsewhere on the Desk

All Dispatches →
Deals

Palantir's 93% revenue surge puts enterprise AI's first-mover gap on the map

August 7, 2026 · 2 min

Earnings

Under Armour cuts full-year revenue outlook as North American demand retreats

August 7, 2026 · 2 min

Crypto加密

Bitcoin and ethereum rally as July jobs miss deepens rate-cut case

August 7, 2026 · 2 min

Regulatory

Interface lifts full-year guidance as tariff refunds and Healthcare billings drive Q2 margin surge

August 7, 2026 · 2 min